Hospitals participating in the first year of Medicare’s Comprehensive Care for Joint Replacement Model reduced payments for lower extremity joint replacement episodes by an average 3.3 percent more than hospitals that did not participate in the model, largely by shifting patients to less intensive post-acute care settings, according to an analysis prepared for the Centers for Medicare & Medicaid Services by the Lewin Group. For example, the share of CJR patients discharged to an inpatient rehabilitation facility fell by a relative 2.2 percentage points while the share discharged to a home health agency rose by 3.9 percentage points. The study found no changes in quality of care as measured by readmission rates, emergency department visits and mortality. CMS implemented the five-year payment model, which qualifies as an advanced alternative payment model under the Quality Payment Program for clinicians, in certain geographic areas in April 2016. The first-year report does not include estimates of the change in Medicare program savings, which were not yet available. 
 

Related News Articles

Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
All 50 states have applied for the Rural Health Transformation Program, the Centers for Medicare & Medicaid Services announced Nov. 5. The program will…
Headline
Bill Gassen, Sanford Health president and CEO and AHA chair-elect designate, and Deb Koski, Sanford Health chief philanthropy officer, discuss how a strong…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…